HyProCure: 10 Years of Clinical Use Creates Enduring Changes for Physicians and Patients

By Karen Sandlin

HyProCure® is the result of GraMedica's passion about creating products that offer better options and better results for both physicians and their patients. A uniquely designed, titanium subtalar stent, HyProCure® instantly realigns the talus on the calcaneus and restores natural joint motion in cases of flexible talotarsal joint dislocation (TTJD). Foot and ankle surgeons estimate that 10% to 30% of the general public suffers from TTJD and its related secondary effects.

Ten years after its introduction and worldwide growth in clinical use, HyProCure® is still making a medical splash. Why all the fuss over such a small piece of titanium? Because it represents a significant change in the design and role of subtalar implants. The FDA acknowledged that difference by clearing HyProCure® with a unique designation as a Class II Sinus Tarsi Stent in 2004.

Dissatisfied with the results of previously available products intended to treat TTJD, Dr. Michael E. Graham created HyProCure® specifically to improve patient outcomes. On a quest ever since to educate physicians and patients around the globe about TTJD, Dr. Graham encourages a shift in physicians' diagnosis and treatment of TTJD. As part of the HyProCure® EOTTS training, he emphasizes recognition and treatment of misaligned feet as the leading source of many seemingly unrelated problems not only within the foot, but also within the knees, hips and back.

HyProCure's® first 10 years have seen many milestones:

- Orthopedic and podiatric surgeons have performed more than 30,000 HyProCure® procedures in 44 countries on every continent;
- More than 1000 physicians have been trained in the HyProCure® EOTTS procedure;
- Educational conferences and lectures about HyProCure have been hosted at hundreds of locations around the globe;
- Peer-reviewed articles about HyProCure® have been published in peer-reviewed journals including: the *Journal of the American Podiatric Medical Association,* the *Journal of Foot and Ankle Surgery* and *Foot and Ankle International;*
- Extensive, ongoing research has supported HyProCure's® success stories with concrete data, including nearly a dozen peer-reviewed, published studies;
- The creation of the first domestic and international HyProCure® Centers of Excellence, a designation that recognizes expertise in performing HyProCure® Extra-Osseous Talotarsal Stabilization (EOTTS) procedures and provision of consummate post-operative care;
- Patients and physicians alike have been inspired to share their HyProCure® success stories via blogs, websites and social media. Some physicians with radio programs have even been inspired to devote entire programs to discussing HyProCure®;
- GraMedica maintains an ongoing public awareness campaign to educate patients about HyProCure® and put them in touch with HyProCure® specialists. The public awareness efforts now include free community foot screenings as well as a website "Doctor Locator" that helps people find trained HyProCure® specialists near them.

Ten years after its introduction and worldwide growth in clinical use, HyProCure® is still making a medical splash.

The first HyProCure® procedure took place in September, 2004. Since then, HyProCure® has helped tens of thousands of patients aged 3-94 improve their quality of life by correcting their misaligned feet. The short procedure, typically only 20 minutes long, instantly re-aligns the foot and ankle with positive life-changing results.

About GraMedica:

GraMedica is a global orthopedic medical device company and leader in the development of life-changing foot and ankle products. Through its sister educational organization, the Graham International Implant Institute (GIII), GraMedica is committed to research, training, certification and support on implantology for foot surgeons worldwide.

To learn more about GraMedica, GIII or HyProCure®, please visit:

www.hyprocuredoctors.com, www.gramedica.com, or www.grahamiii.com or *click here.*